Lupin Launches Generic Dasatinib Tablets in the US After FDA ANDA Approval
Lupin Limited announced the launch of dasatinib tablets in multiple strengths in the United States following approval of its Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA).
The product has been developed in partnership with Pharmascience Inc.
Available Strengths
Lupin’s dasatinib tablets are available in:
20 mg
50 mg
70 mg
80 mg
100 mg
140 mg
All strengths are bioequivalent to Sprycel (dasatinib) tablets from Bristol-Myers Squibb.
Approved Indications
Dasatinib is indicated for the treatment of:
Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML who are resistant or intolerant to prior therapy, including imatinib
Adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) resistant or intolerant to prior therapy
Paediatric patients 1 year and older with Ph+ CML in chronic phase
Paediatric patients 1 year and older with newly diagnosed Ph+ ALL in combination with chemotherapy
Expanding Access to Oncology Generics
The US launch strengthens Lupin’s oncology portfolio and supports broader access to affordable targeted therapies for blood cancers.
Dasatinib is a tyrosine kinase inhibitor (TKI) widely used in the management of CML and Ph+ ALL.
About Lupin
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India. The company markets products in over 100 countries and focuses on:
Branded and generic formulations
Complex generics
Biotechnology products
Active pharmaceutical ingredients (APIs)
About Pharmascience
Pharmascience Inc. is one of Canada’s largest pharmaceutical manufacturers, headquartered in Montreal. The company supplies high-quality medicines to 50+ countries and operates with an agile, globally focused business model.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!